Results 31 to 40 of about 7,444 (141)
Scientific ReportsRifaximin is FDA-approved for treatment of irritable bowel syndrome with diarrhea (IBS-D), but poor solubility may limit its efficacy against microbes in the mucus layer, e.g. Escherichia coli. Here we evaluate adding the mucolytic N-acetylcysteine (NAC)
Gabriela Leite +12 more
doaj +1 more source
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. [PDF]
PLoS ONE, 2013 Hepatic encephalopathy (HE) represents a dysfunctional gut-liver-brain axis in cirrhosis which can negatively impact outcomes. This altered gut-brain relationship has been treated using gut-selective antibiotics such as rifaximin, that improve cognitive ...
Jasmohan S Bajaj +15 more
doaj +1 more source
Journal of Hospital Medicine, EarlyView.Abstract Health‐related social needs (HRSN) significantly influence patient outcomes, yet they are rarely integrated into point‐of‐care decision‐making. We developed a process to embed HRSN‐informed and HRSN‐targeted care recommendations directly into three electronic health record‐integrated high‐use clinical pathways—cirrhosis, diabetes, and ...
Karthik Warke Rohatgi +5 more
wiley +1 more source
JPGN Reports, EarlyView.Abstract Hyperornithinemia‐hyperammonemia‐homocitrullinuria (HHH) syndrome is a rare metabolic condition that can cause lethargy, ataxia, tachypnea, nausea, vomiting, seizures, coma, and acute liver failure. We present a 26‐month‐old female with acute liver failure who was diagnosed with HHH 1 week after admission. Histology revealed an acute hepatitic
Tierra L. Mosher +6 more
wiley +1 more source
Scientific Reports, 2022 Current knowledge suggests that infection by carbapenem-resistant enterobacteria is preceded by gut colonization. It is hypothesized that colonization is eradicated by non-absorbable antibiotics like rifaximin.
Eleni Xenofontos +8 more
doaj +1 more source
Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges
Neuroprotection, EarlyView.Antimicrobial agents exert neuroprotective effects through modulation of interconnected pathways. Tetracyclines, macrolides, antimalarial agents, sulfones, and antiparasitic agents suppress neuroinflammation, oxidative stress, and apoptosis while preserving mitochondrial function and neurotransmission.
Mohammad Amin Manavi +5 more
wiley +1 more source
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
British Journal of Pharmacology, EarlyView.Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Recent Development of Endo‐hepatology
DEN Open, Volume 7, Issue 1, April 2027.ABSTRACT Endo‐hepatology is a rapidly evolving field encompassing endoscopic diagnosis and treatment of hepatobiliary diseases, primarily using endoscopic ultrasound (EUS). Since its conceptualization in 2012, the field has expanded dramatically alongside advances in interventional EUS. A landmark 2024 review broadened the concept to include endoscopic
Akira Yamamiya +3 more
wiley +1 more source
Rifaximin has the potential to prevent complications of cirrhosis
Therapeutic Advances in Gastroenterology, 2018 Background: Cirrhosis-related complications are associated with poor prognosis. With our analyses, we examined the potential benefit of rifaximin in reducing the risk of developing cirrhosis-related complications.
Steven L. Flamm +3 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 871-889, October 2026.The intestinal microbiome is a key regulator of immune homeostasis, metabolism, and epithelial barrier integrity. In patients with malignant hematological diseases, particularly those undergoing hematopoietic stem cell transplantation, microbiome perturbations by reduced diversity, pathobiont expansion, and loss of beneficial metabolites are common as ...
Bálint Gergely Szabó +7 more
wiley +1 more source